Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
The planned tests are intended to provide additional comparative data of WP1122 and its close analogs.
- The planned tests are intended to provide additional comparative data of WP1122 and its close analogs.
- Management believes the mechanism of action of 2-DG and WP1122 is very different from other drugs being developed for COVID-19.
- Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.
- Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition, such as WP1122.